Fate Therapeutics (FATE) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Molecular Partners (MOLN) over the past year, losing 10.8% versus a loss of 37.5%. Over five years, MOLN leads with a -77.9% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $96.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | MOLN |
|---|---|---|
| Share price | $0.919 | $2.53 |
| Market cap | $111.82M | $96.80M |
| 1-day change | -9.01% | -5.25% |
| YTD return | -6.22% | -42.07% |
| 1-year return | -10.78% | -37.50% |
| 5-year return | -98.25% | -77.87% |
| EPS (TTM) | $-1.03 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.65M | — |
| Revenue growth (YoY) | -51.24% | — |
| Net income (latest FY) | $-136.31M | — |
| Operating margin | -2222.45% | — |
| Net margin | -2051.08% | — |
| 52-week high | $3.23 | $5.36 |
| 52-week low | $0.90 | $2.52 |
| Distance from 52-week high | -71.55% | -52.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +522.42% | +295.64% |
| Average volume | 1.53M | 1.63K |
| Shares outstanding | 121.67M | 38.34M |
| Employees | 161 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed MOLN by 26.7 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
FATE vs MOLN FAQ
Which is bigger, Fate Therapeutics or Molecular Partners?
Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $96.80M for Molecular Partners (MOLN).
Which stock has performed better over the past year, FATE or MOLN?
FATE returned -10.78% over the past 12 months, compared with -37.50% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.